To include your compound in the COVID-19 Resource Center, submit it here.

New data from Zafgen's Prader-Willi study

Zafgen Inc. (NASDAQ:ZFGN) presented secondary endpoint data from the Phase III bestPWS (ZAF-311) trial evaluating subcutaneous beloranib ( ZGN-440) to treat Prader-Willi syndrome. Data were presented at the

Read the full 282 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE